Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

The Pfizer stock's long-term trajectory looks predominantly bullish, as indicated in the quarterly chart. A closer look shows that between 1999 and 2009, there was a clear emergence of a bull flag ...

Pfizer's stock (NYSE:PFE)(NEOE:PFE:CA) has notably lagged behind the S&P 500 index since I wrote my previous analysis in early May. I was extremely bearish and gave PFE a "Strong Sell" rating.

My final reason for buying more Pfizer stock is that I'll get paid nicely to wait and see if the drugmaker lives up to Wall Street's growth outlook. Pfizer's forward dividend yield currently stands at ...

Pfizer demonstrated strong financial performance in the fourth quarter of 2024, with revenues reaching $63.6 billion for the full year, hitting the upper end of guidance. The company's earnings ...

According to InvestingPro analysis, the stock currently appears undervalued compared ... Financial Performance and Guidance. Pfizer's second-quarter results for 2024 demonstrated the company's ...

Pfizer’s financial outlook for 2025 has been a focal point for investors and analysts. The company has maintained its revenue guidance for fiscal year 2025 at $61.0-64.0 billion, with the COVID ...

Pfizer and S&P 500 Performance During 2007-08 Crisis PFE stock declined from nearly $12 in September 2007 (pre-crisis peak) to $7 in March 2009 (as the markets bottomed out), implying it lost 45% ...

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board of Directors. Starboard Value said they had scheduled a meeting with ...

Pfizer Inc. (NYSE: PFE), a global biopharmaceutical giant with a market capitalization of $139.52 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...